Brentuximab vedotin is an antibody-drug conjugate used to treat Hodgkin lymphoma and systemic anaplastic large cell lymphoma. It consists of the monoclonal antibody cAC10 linked to the microtubule inhibitor MMAE. When the antibody binds to CD30 proteins on lymphoma cells, the complex is internalized and MMAE is released, disrupting the microtubule network and causing cell death. Brentuximab vedotin allows targeted delivery of the cytotoxic agent to minimize side effects compared to conventional chemotherapy. Common side effects include neuropathy, nausea, fatigue, and low blood cell counts.